Abstract: A method of remediation of soil and groundwater containing hydrocarbons and halogenated compounds. The method includes introducing a remediation composition into the soil that includes: (a) a first bioremediation material including a first blend of organisms capable of degrading the hydrocarbons; (b) a second bioremediation material including a second blend of organisms differing from the first blend of organisms that is chosen for degrading the halogenated compounds; (c) an organic compound such as a complex carbohydrate (e.g., food grade starch); and (d) a third blend of organisms degrading the organic compound. The degrading of the organic compound breaks the complex carbohydrate into smaller molecules that are utilized by the microorganisms of at least one of the first and second bioremediation materials during the degrading of the hydrocarbons and the halogenated compounds.
Abstract: The invention relates to methods of treating baldness, treating alopecia, promoting hair growth, and/or promoting hair follicle development and/or activation or stimulation on an area of the skin of a subject (for example, a human) by subjecting said area of the skin to integumental perturbation. Integumental perturbation can be used in combination with other treatments for promoting hair growth. The invention provides devices for integumental perturbation for promoting hair growth, and provides pharmaceutical compositions for use in combination with integumental perturbation for promoting hair growth.
Type:
Grant
Filed:
September 24, 2021
Date of Patent:
April 1, 2025
Assignee:
FOLLICA, INC.
Inventors:
Shikha P. Barman, William D. Ju, Scott C. Kellogg, Stephen M. Prouty, Eric Schweiger, Seth Lederman, Mary Osbakken, Alan D. Schinazi
Abstract: The invention provides method for preparing amnion tissue grafts, as well as the grafts themselves. In specific embodiments, the tissue graft comprises a single layer of dried amnion from an umbilical cord.
Abstract: The present invention provides methods, agents, compounds, and compositions useful for administering to subjects having or at risk of having anemias. In certain embodiments, methods herein comprise administering two agents to a subject, which are useful for the treatment of an anemia.
Abstract: Methods and techniques for controlled printing of a cell sample for karyotyping are provided. The methods can involve matrix printing using on-the-fly printing or dispensing to accurately spread cells within at least one cell sample on a surface in preparation for karyotyping, and further analysis. Advantageously, the methods result in a uniform distribution of chromosomes of the cell suspension or sample on the surface of a substrate which can be substantially discretely identified, and also provide for efficiency in a subsequent staining process and any further analysis of the stained chromosomes using a microscope or other imaging device.
Type:
Grant
Filed:
November 22, 2021
Date of Patent:
March 25, 2025
Assignee:
Biodot, Inc.
Inventors:
Brian L. Kirk, Anthony V. Lemmo, Thomas C. Tisone
Abstract: Provided are defined culture media for culturing pluripotent stem cells in a suspension culture devoid of substrate adherence, the defined culture media comprising an effective amount of a protease inhibitor; a GSK3? inhibitor and at least one agent selected from the group consisting of a protease inhibitor and a WNT3A polypeptide; a WNT3A polypeptide and a stabilizing agent thereof with the proviso that said stabilizing agent is not a lipid vesicle; and/or a GSK3? inhibitor, with the proviso that the medium is devoid of an ERK1/2 inhibitor. Also provided are cell cultures and methods of suing same.
Abstract: Provided herein are compositions and methods for the cryopreservation of immune cells, such as peripheral blood mononuclear cells (PBMCs) by pre-treating the cells with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein) prior to freezing. Kits for practicing the methods are also provided herein.
Type:
Grant
Filed:
April 7, 2020
Date of Patent:
March 18, 2025
Assignee:
HTYR Acquisition LLC
Inventors:
Yosef Refaeli, Brian C. Turner, Thomas R. Payne
Abstract: Described herein are methods for providing an in vitro intestinal model system, e.g., using primary cells instead of cell lines and/or cancerous cells.
Type:
Grant
Filed:
September 6, 2023
Date of Patent:
March 11, 2025
Assignee:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Donald E. Ingber, Magdalena Kasendra, Alexandra Sontheimer-Phelps, Alessio Tovaglieri
Abstract: The present invention concerns the therapeutic use of extracellular vesicles isolated from a genetically modified cell line over-expressing SerpinB3. In particular, said therapeutic use aimed at the treatment of acute pathologies characterized by ischemic or inflammatory tissue damage or by cell injury due to oxidative stress, such as cardiac, cerebral, intestinal, renal or limb ischaemia. Further examples of use consist of the preservation of transplant organs, including heart, lung, liver, bladder, pancreas and intestine. In a further aspect the invention relates to the use of a pharmaceutical composition comprising extracellular vesicles isolated from a genetically modified cell line over-expressing SerpinB3 and a pharmaceutically acceptable vehicle.
Abstract: A pH-modulating poly(glycerol sebacate) composition includes poly(glycerol sebacate) and at least one pH-modulating agent associated with the poly(glycerol sebacate). A process of making a pH-modulating poly(glycerol sebacate) composition includes forming a poly(glycerol sebacate) by a water-mediated reaction from glycerol and sebacic acid and associating at least one pH-modulating agent with the poly(glycerol sebacate). A process of modulating a pH of a buffered aqueous solution includes placing a pH-modulating poly(glycerol sebacate) composition in a buffered aqueous solution. The pH-modulating agent is released into the buffered aqueous solution during degradation of the poly(glycerol sebacate) to reduce a decrease in pH of the buffered aqueous solution caused by degradation of the poly(glycerol sebacate).
Type:
Grant
Filed:
August 18, 2021
Date of Patent:
February 11, 2025
Assignee:
THE SECANT GROUP, LLC
Inventors:
Peter D. Gabriele, Jeremy J. Harris, Charles Brendan Nicholson, Steven Lu, Brian Ginn
Abstract: Disclosed are compositions comprising a MSC secretome preparation and cannabinoids and methods of the use of said compositions for the treatment of inflammatory conditions.
Type:
Grant
Filed:
July 20, 2020
Date of Patent:
February 4, 2025
Assignee:
DIRECT BIOLOGICS, LLC
Inventors:
Kenneth Allen Pettine, Timothy Alexander Moseley
Abstract: A method for fixing a biological sample includes delivering energy through a biological sample that has been removed from a subject, while fixing the biological sample. A change in speed of the energy traveling through the biological sample is evaluated to monitor the progress of the fixation. A system for performing the method can include a transmitter that outputs the energy and a receiver configured to detect the transmitted energy. A computing device can evaluate the speed of the energy based on signals from the receiver.
Type:
Grant
Filed:
February 9, 2023
Date of Patent:
February 4, 2025
Assignee:
Ventana Medical Systems, Inc.
Inventors:
David Chafin, Michael Otter, Abbey Pierson, Jefferson Curtis Taft
Abstract: Disclosed are methods for treating platelet compositions (e.g. platelet concentrates and/or platelet lysates) with electron beam radiation, where the compositions are in a frozen state during irradiation with the e-beam radiation. The methods can be conducted using e-beam radiation at doses effective to reduce the pathogen content of the compositions while retaining highly beneficial bioactivities of the compositions. Also disclosed are compositions preparable by the methods, and methods and compositions involving the use of the e-beam treated materials.
Abstract: A method for mosquito control is provided in the form of mosquito larvicide carrying insects which can be introduced in a mosquito population to thereby control the mosquito population. The larvicide carrier insects may include artificially generated adult insect carriers of a mosquito larvicide in which the mosquito larvicide has minimal impact on the adult insect carrier and which mosquito larvicide affects juvenile mosquito survival or interferes with metamorphosis of juvenile mosquitoes to adulthood. The larvicide carrier insects may be either male or female and may include mosquitoes and non-mosquito insects.
Abstract: The present disclosure relates to the use of laminin-521 in obtaining retinal pigment epithelium (RPE) cells. Pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in totally defined and xeno-free conditions. A first cell culture medium contains a growth factor, and a second cell culture medium does not contain growth factor. The stem cells are first exposed to the first cell culture medium, then exposed to the second cell culture medium for a longer time period. After a number of weeks, clinical grade RPE cells are obtained from the stem cells.
Abstract: An organ, a tissue or cells of a living body can be preserved stably at a non-freezing low temperature without damaging the organ, the tissue or the cells, by the method of preserving an organ, a tissue or cells of a living body by using the low temperature damage alleviating agent or the necrosis inhibitor comprising a coffee extract of the present invention, or a medium comprising a coffee extract.
Abstract: The present invention pertains to periostin compounds for use in the prevention and treatment of haematological complications, such as adverse events from therapy or haematological diseases. In context of the present invention a therapeutic was developed for enhancing haematopoiesis in patients and to support haematopoietic stem cell (HSC) transplantation (HSCT) by administration of periostin compounds to patients or stem cell donors, or by contacting HSC directly with periostin compounds, for example ex vivo, to improve a transplant HSC preparation. The present invention provides periostin derived compounds such as polypeptides, peptides, nucleic acids, and other periostin-derived agents, that are used both in therapeutic applications and for improving haematopoiesis, for example in stem cell donor subjects or to treat HSC in vitro.
Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.
Type:
Grant
Filed:
June 17, 2021
Date of Patent:
December 10, 2024
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Farah Natoli, Gaozhong Zhu, Jennifer Terew, Yuan Jiang, Jamie Tsung, Zahra Shahrokh, Brian Vernaglia, Jing Pan, Richard Pfeifer, Pericles Calias
Abstract: A method for preparing a stem cell-based, human derived composition containing conditioned cell culture medium is disclosed. The method comprises culturing cells of two or more eukaryotic cell lines to form conditioned culture media, separating the cultured cells from the conditioned culture media, and combining conditioned culture media to form a bioactive composition. This composition is used to treat citrus plants that have been infected by one or more insect-vectored bacterial and/or pathogenic infections such as Citrus Greening. This method consists of applying the conditioned media one or more times to the plant. Use of this treatment may have application to a variety of other agricultural conditions.